This section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article contentNew automated platform is designed to improve the quality, efficiency, and consistency of DNA extraction and concentration from large-volume blood and plasma samples, supporting downstream assays capable of detecting disease-associated signals at MRD sensitivity levels.
Sign In or Create an Account
or View more offersArticle content
SAN DIEGO — Invivoscribe®, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced that commercial shipments of the PrepQuant™ System have begun in North America. First unveiled at the American Association for Cancer Research Annual Meeting in April 2026, PrepQuant is now being delivered to customers, marking the platform’s progression from development and validation into commercial deployment.
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
The commercial milestone extends Invivoscribe’s capabilities into laboratory instrumentation and addresses a critical bottleneck in highly sensitive molecular testing: efficiently recovering, concentrating, and quantifying DNA from larger blood and plasma inputs. PrepQuant is assay agnostic, designed to produce concentrated genomic DNA and cell-free DNA (cfDNA) suitable for a full range of downstream molecular workflows, including MRD assays intended to detect very low levels of residual disease.
Article contentArticle contentMRD Sensitivity Starts Before the AssayArticle content
As MRD testing moves toward greater sensitivity, sample preparation becomes more critical to recovering rare disease-associated molecules. Larger inputs can increase the amount of DNA available for analysis, but they also create challenges involving extraction efficiency, DNA recovery, concentration, processing time, and consistency.
Article content
Many laboratories currently rely on separate protocols and instruments for extraction, concentration, and quantification. Each transfer can add hands-on time and create another opportunity for variability or error, while fragmented workflows can limit throughput as testing volumes grow. The concept for PrepQuant was informed by operational challenges observed across LabPMM, Invivoscribe’s global network of clinical laboratories.
Article contentYou cannot detect what you do not recover.Article contentAn Integrated Platform for Larger Sample InputsArticle content
PrepQuant integrates nucleic acid extraction, concentration, and quantification into one automated platform. By replacing multiple instruments and protocols with a standardized workflow, the system is designed to reduce hands-on labor, sample handling, variability, operating costs, and bench-space requirements.
Article content
The assay agnostic system generates highly concentrated genomic DNA and cfDNA for next-generation sequencing, capillary electrophoresis, quantitative PCR, and digital PCR assays. It is designed and validated for blood, plasma, and bone marrow samples, with additional sample types under development. Its broad compatibility establishes a platform for future PrepQuant kits and applications.
Article contentA Platform Opportunity Across the MRD Testing WorkflowArticle content
PrepQuant extends Invivoscribe’s standardization strategy upstream of molecular analysis, complementing the company’s MRD assays, bioinformatics, and global clinical testing capabilities. Automation and standardization can make sophisticated workflows more practical as testing volumes grow and can support greater consistency across research, reference, and clinical laboratories.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content“As precision oncology advances and MRD testing becomes mainstream, laboratories cannot focus on analytical sensitivity alone,” said Jeff Miller, CEO and CSO of Invivoscribe. “The ability to generate reliable molecular data begins upstream, with how the sample is processed and how effectively the available nucleic acid is recovered and consistently quantified. PrepQuant reflects our broader view that standardization across the entire testing continuum will be increasingly important as molecular MRD testing becomes integral both to monitoring disease and evaluating the effectiveness of new therapies.”Article contentCommercial AvailabilityArticle content
Initial PrepQuant Systems are now being delivered to customers in North America, with European availability early in 2027. Invivoscribe is currently developing additional PrepQuant kits to expand the platform’s capabilities to address the entire range of molecular testing workflows.
Article content
Laboratories interested in purchasing PrepQuant, requesting a quotation, or learning more may contact Invivoscribe at [email protected].
Article contentAbout InvivoscribeArticle content
Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For more than 30 years, Invivoscribe has advanced precision medicine by providing high-quality standardized reagents, assays, bioinformatics tools, and clinical testing services, while supporting pharmaceutical partners through clinical trials, companion diagnostic development, and global regulatory expertise. With the launch of the PrepQuant System, the Invivoscribe ecosystem now includes instrumentation, extending the company’s standardization efforts into the critical pre-analytical workflows that support accurate and reproducible molecular testing. For more information, visit www.invivoscribe.com, contact [email protected], or follow Invivoscribe on LinkedIn.
Article contentArticle contentArticle contentArticle contentView source version on businesswire.com: Article content
https://www.businesswire.com/news/home/20260902353365/en/
Article contentArticle content
Contacts
Article content[email protected]Article content